A clinical-stage biopharmaceutical business with a focus on cardiovascular disease main information.

Amarin reports top-line results from AMR101 Phase 3 trial for treatment of high triglycerides Amarin Company plc , a clinical-stage biopharmaceutical business with a focus on cardiovascular disease, reported positive today, statistically significant top-line outcomes from the MARINE research, its first Phase 3 clinical trial of lead drug applicant AMR101. The study’s major endpoint, the % change in triglyceride amounts from baseline to week 12, was fulfilled for both 4 gram and 2 gram dose groupings. The MARINE study was required to meet a stringent degree of statistical significance of 1 percent , while agreed in the Company’s SPA with the FDA main information . Twenty-five % of individuals were on history statin therapy.